EP
SPRO icon

Eversept Partners’s Spero Therapeutics SPRO Stock Holding History

Eversept Partners’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-59,639
Closed -$519K – 97
2022
Q1 		$519K Buy
+59,639
New +$611K 0.04% 73

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Eversept Partners's SPRO Position: Q2 2022 in Review

Eversept Partners sold out of Spero Therapeutics (SPRO) in Q2 2022, closing a stake of 59,639 shares — an estimated $519K sold.

Eversept Partners first reported a position in SPRO in Q1 2022 and held it in 1 quarter. The position peaked at $519K in Q1 2022. 79 funds tracked by Wall St. Rank hold SPRO as of Q2 2022.

  • Eversept Partners reported no remaining Spero Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Eversept Partners sold 59,639 Spero Therapeutics shares in Q2 2022, an estimated $519K.
  • Eversept Partners first reported a position in Spero Therapeutics in Q1 2022 and held it in 1 quarter.
  • Eversept Partners's Spero Therapeutics position peaked at $519K in Q1 2022.
  • 79 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2022.

Based on Eversept Partners's 13F filing for Q2 2022, filed 15 Aug 2022.